Larry D. Anderson, Jr, MD, PhD, discusses the rationale behind using chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma, data from the KarMMa trial, and other trials investigating this treatment.
Larry D. Anderson, Jr., MD, PhD
Advertisement
Larry Anderson Jr., MD, PhD, is a professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Hematology/Oncology.
Articles by Larry D. Anderson, Jr., MD, PhD
Larry D. Anderson, Jr, MD, PhD, discusses the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
